Webcast: EDAP Presentation at Roth Capital Conference EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, presented at the Roth Capital Partners New York Conference on September 6, 2006 at the Westin Time Square Hotel in New
EDAP TMS S.A. to Present at Roth Capital Conference in New York Lyon, France, August 24, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced management will present at the Roth Capital Partners New York
EDAP TMS S.A. to Release 2006 Second Quarter Financial Results August 8, 2006 Lyon, France, August 3, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , will release its second quarter financial results for the period ending June 30, 2006 on Tuesday, August 8, 2006 after the market close.
Ablatherm FDA Study in Triangle Business Journal EDAP's Ablatherm-HIFU FDA clinical study was recently featured in the Triangle Business Journal. The article is viewable online at http://triangle.bizjournals.com/triangle/stories/2006/07/17/focus4.html . A patient treated at Duke University
EDAP TMS S.A. Announces $7.5 Million Placement Lyon, France, July 27, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) announced that it has entered into a securities purchase agreement with selected accredited investors pursuant to which an aggregate of 961,676 of the company's ordinary shares in the form of
Ablatherm-HIFU experience highlighted by UK Prostate Cancer Charity The Prostate Cancer Charity , the largest and most comprehensive charity in the UK focused on prostate cancer, recently included a 4-page detailed overview of HIFU treatment for localized prostate cancer in its widely distributed